Perrigo Company PLC
$ 10.90
-2.42%
11 Jun - close price
- Market Cap 1,546,952,000 USD
- Current Price $ 10.90
- High / Low $ 11.19 / 10.55
- Stock P/E N/A
- Book Value 18.09
- EPS -12.93
- Next Earning Report 2026-07-31
- Dividend Per Share $1.16
- Dividend Yield 9.99 %
- Next Dividend Date 2026-06-16
- ROA 0.02 %
- ROE -0.52 %
- 52 Week High 26.20
- 52 Week Low 9.00
About
Perrigo Company plc is an American Irish registered manufacturer of private label over-the-counter pharmaceuticals.
Analyst Target Price
$16.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-26 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-27 | 2024-11-06 | 2024-08-02 | 2024-05-07 | 2024-02-27 | 2023-11-07 | 2023-08-08 |
| Reported EPS | 0.43 | 0.77 | 0.05 | 0.57 | 0.6 | 0.36 | 0.81 | 0.53 | 0.29 | 0.86 | 0.64 | 0.63 |
| Estimated EPS | 0.31 | 0.8133 | 0.46 | 0.59 | 0.57 | 0.95 | 0.81 | 0.46 | 0.23 | 0.83 | 0.63 | 0.51 |
| Surprise | 0.12 | -0.0433 | -0.41 | -0.02 | 0.03 | -0.59 | 0 | 0.07 | 0.06 | 0.03 | 0.01 | 0.12 |
| Surprise Percentage | 38.7097% | -5.324% | -89.1304% | -3.3898% | 5.2632% | -62.1053% | 0% | 15.2174% | 26.087% | 3.6145% | 1.5873% | 23.5294% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-31 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.36 |
| Currency | USD |
Previous Dividend Records
| Jun 2026 | Mar 2026 | Dec 2025 | Jan 1970 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-06-16 | 2026-03-24 | 2025-12-16 | None | 2025-06-17 | 2025-03-25 | 2024-12-17 | 2024-09-17 | 2024-06-18 | 2024-03-26 |
| Amount | $0.29 | $0.29 | $0.29 | $0.29 | $0.29 | $0.29 | $0.276 | $0.276 | $0.276 | $0.276 |
Next Dividend Records
| Dividend per share (year): | $1.16 |
| Dividend Yield | 9.99% |
| Next Dividend Date | 2026-06-16 |
| Ex-Dividend Date | 2026-05-29 |
Recent News: PRGO
2026-06-10 20:11:58
Perrigo Company's President and CEO, Patrick Lockwood-Taylor, has resigned due to personal conduct violations, effective immediately. The board has appointed Albert A. Manzone as interim President and CEO and reaffirmed its full-year 2026 financial outlook to ensure strategic continuity. Analysts currently rate PRGO stock as a Buy with a $17.00 price target, though Spark AI Analyst has a Neutral rating due to weak financial performance.
2026-06-10 17:40:10
Perrigo (PRGO) stock rose by 1.7% following renewed takeover speculation. Reports suggest Germany-based Stada Arzneimittel AG and its private equity owner, CapVest, may be interested in acquiring Perrigo, based on an "uncooked" alert from Betaville.
2026-06-09 20:11:58
Perrigo Co plc EVP and President of CSCI, Roberto Khoury, exercised Restricted Stock Units (RSUs) on June 5, 2026, converting into 17,902 ordinary shares valued at $10.83 per share. Concurrently, 9,346 ordinary shares were withheld to cover tax obligations. These transactions represent routine equity compensation vesting and are not discretionary buying or selling of Perrigo stock.
2026-06-09 13:10:18
Perrigo Company plc's former CEO, Patrick Lockwood-Taylor, reported the exercise of 25,230 Restricted Stock Units (RSUs) into ordinary shares. To cover tax obligations, 12,906 ordinary shares were disposed of at $10.83 per share. Following these compensation-related transactions, Lockwood-Taylor directly holds 136,076 ordinary shares and 50,458 RSUs, indicating an exercise-and-tax-withholding event rather than an open-market sale or purchase.
2026-06-09 02:10:18
Perrigo, now a pure-play consumer healthcare company, faces an uncertain recovery path due to category weakness, a leadership transition, and infant formula pressures. The company is the largest private-label OTC manufacturer in the US and expects low single-digit growth in its private-label business over the next five years. While a new leader could be strategic, challenges remain in the fragmented OTC market.
2026-06-08 21:10:21
Perrigo's CEO, Murray S. Kessler, has resigned from his position and the board of directors, effective immediately. Patrick Lockwood-Taylor, currently President, Consumer Self-Care Americas, has been appointed as his successor. The company reaffirmed its financial guidance for fiscal year 2026, including organic net sales growth, adjusted operating margin improvement, and adjusted diluted EPS growth.
